Hello, and welcome to the SYNLAB full year 2023 financial results. Throughout the call, all participants will be in a listen-only mode, and afterwards, there will be a question-and-answer session. Please note that this call is being recorded. Today, I'm pleased to present Mathieu Floreani. Please begin your meeting. Thank you. Good afternoon, good morning, ladies and gentlemen, and welcome to our call, where we will present our 2023 results. As usual, I'll begin with the highlights. Sami will then provide a deeper dive into the financials before I take over again and conclude with our business segments and the outlook for 2024. After the presentation, we'll open the floor to your questions. The year 2023 confirmed that we are well on track on our journey of margin improvement, product recovery, and portfolio management. We can start with our highlights now on last year on slide five. We have concluded the year 2023 with a strong financial performance, in line with our 2023 guidance, and this in a moving and challenging global macroeconomic environment. I'm just checking, do we see the slides? Seems not. Okay, we should, we should be there. Sorry for that. So our 2023 performance was supported by a solid organic growth at 6.4% for the year, which together with our efforts on productivity management, led to drive EBITDA margin to improve to 16.6%. 2023 was also the year of delivery of our active portfolio management strategy, with significant divestments in segments and geographies. As a reminder, we have sold our Swiss, Polish, and Ukrainian activities, as well as our non-strategic veterinary activities, U.K., and continental. The net proceeds from these 2023 disposals amount to EUR 336 million, and they supported both our acquisition, acquisition strategy, sorry, and our leverage decrease through debt repayments. SYNLAB leverage at year-end 2023 stands below 3 at 2.9 x. As a reminder, the portfolio management consists also in reviewing our portfolio of activity within each country, terminating, for example, unfavorable customer relationships. So if we now go to slide seven, where we review the highlights of our 4U transformation strategy along the four quadrants. So I've mentioned the strong organic growth continued in the quarter, driven again by overachieving our 4U initiatives and positive price developments. Our focus on the customer experience in retail paid off with an NPS at 88%. On SALIX, our efficiency program, we continued delivering, reaching now an amount of EUR 40 million in 2023, which is double compared to previous years in terms of savings. This was an all-time high, and we intend to continue pushing for these levels in the future. In 2023, we completed eight acquisitions in four countries for an acquired EV of approximately EUR 90 million. And as mentioned before, our divestment activity was intense with the sale of several businesses. So for the fourth quarter, we can go to slide seven to cover ESG, which is an important aspect of this fourth pillar. Yes. So the implementation of our SYNLAB ESG strategy is indeed progressing very nicely on all fronts. We continue leading the scientific publications in our industry, with now 332 publications completed in 2023. And we're also proud of having launched the first test for bipolar disorder detection. We have made good progress on employee engagement, on training hours or CO2 reduction. On citizenship, the implementation of an ESG and human rights due diligence process for the entire value chain is a great and complex step forward. And finally, the SYNLAB Foundation was very successful this year, completing an ambitious project on colorectal cancer detection in challenged communities, in Portugal. This progress was also recognized independently. We are happy to share the good news on the ratings fronts with ISS ESG full year 2023 prime status, and the MSCI ESG full year 2023 A status. On slide eight, I've mentioned our score for NPS reached 88%, and this is based on rigorous and harmonized tracking with Feedtrail, and we gathered more than 1 million feedbacks from our patients and customers. So we are very encouraged to continue progressing on this path of excellence in our service delivery. Let me now hand over to Sami to cover the financials of the presentation of today. ... Thank you, Mathieu. Good afternoon, everyone. I'm very pleased to walk you through the Q4 and full year 2023 financial performance of the SYNLAB Group. And let's start with the revenue on page 10. The Q4 2023 revenue reported, the reported revenue, sorry, stands at EUR 645 million, -8% revenue variance year-over-year. The pro forma revenue includes the additional revenue as if 2022 and 2023 acquisition had been consolidated on the first of January of each year, and the lower revenue as if 2022 and 2023 disposals had been deconsolidated on the first of January of each year. Disposals are Switzerland, Ukraine, Poland business, and veterinary business in U.K., Germany, and Belgium, and as well as the Spanish activities. EUR 62 million of revenue reduction from COVID-19, now bridging the revenue between 2022 and 2023 Q4. Q4 2023 COVID organic nominal revenue stands at EUR 5 million. We have EUR 29 million of underlying organic growth, 4.9% of growth. The Q4 2023 price is up 1.8%, reflecting the positive effect of price indexations in several countries from the North and East and South segments. Q4 2023 volume is up 3.1%, with strong growth in Germany, and we'll see it later. We have a nominal FX impact in Q4 and overall EUR 14 million revenue from the eight acquisitions completed in 2023. Jumping now on page 11 on the full year 2023, where we have, again, strong underlying growth. The full year 2023 reported revenue stands at EUR 2,635 million, -19% revenue variance year-over-year. Same four elements to explain the pro forma revenue development. COVID-19 testing, EUR 40 million in full year 2023, EUR 75 million reduction compared to full year 2022. The underlying organic growth stands at 6.4%, with EUR 149 million growth. Very strong performance above our initial budget from over delivery of the 4U growth initiatives and a very strong Q1 2023. We have a nominal EUR 9 million negative effects from the strength of the Mexican peso, offset by the weakening of the GBP and other emerging currencies. 2023, EUR 55 million of pro forma revenue for 2023, 1.6% of growth. The full year 2023 includes EUR 85 million revenue from disposed businesses during the year. The reported revenue in 2022 of those businesses was EUR 205 million, including COVID revenue. Page 12, the full year 2023, EBITDA performance. The 2023 reported adjusted EBITDA stands at EUR 438 million, versus the EUR 753 million in 2022. The EBITDA organic evolution explains the bulk of the variance. The 299 million organic EBITDA drop we have, despite 38 million positive price from underlying business, we have 69 million inflation, 3.4% overall on the base business, with strong inflation on PEX at 4%. We have increasing, but still limited inflation on MatEx at 2.3%, mostly consumable and external labor, as our reagent costs are, for the most part, fixed with multi-year contracts. We still have strong inflation of, on OpEx at 3.7%, fluctuating with energy and fuel costs, with ongoing reduction. The rest of the elements explain the net drop of organic EBITDA, are COVID-19 volume drop, partially offset by positive organic volume growth and the SALIX benefit of EUR 40 million, reflecting the recovery of the productivity of the underlying business post COVID-19. The year-to-date EBITDA margin of the group stands at 16.6%, within the 16%-18% range guidance communicated more than one year ago. The Q4 2023 EBITDA margin stands at 17%, 4.1 points higher than the Q4 2022 low margin point. 2023 reported EBITDA margin is at the low point, as anticipated, with the COVID-19 ramp down that is now over, and the positive impact of portfolio management measures already implemented. The 2023 pro forma margin, meaning adjusted for the disposals, is at 16.9% margin. Looking now at the P&L on page 13, the bridge from EBITDA to net profit and from reported to adjusted financials. EBITDA first, we have EUR 15 million adjustment, mostly acquisitions related costs, including PMI costs. The adjusted operating profit is at EUR 194 million. It, it is down EUR 313 million from 2022. Again, COVID-19 price and volume reduction. The adjustment between operating profit and adjusted operating profit is a standard rounded EUR 50 million amortization of customer list and EUR 68 million of goodwill impairment in Germany from higher WACC and inflation assumptions, mostly on PEX. The net finance result is higher by EUR 83 million compared to 2022. EUR 25 million net interest expense increase, EUR 51 million from financial instruments revaluation, lower derivatives gain. The tax line is decreasing compared to 2022, and the adjusted effective tax rate is roughly stable at 26.3%. The 2023 net profit includes EUR 184 million of profit from the 2023 disposals. The 2023 adjusted net profit stands at EUR 44 million, down EUR 303 million year-over-year. The profit from the disposals is excluded from the adjusted net profit. The adjusted EPS of the group is at EUR 0.20. Moving now to cash on page 13. The full year 2023 unlevered free cash flow is EUR 74 million, with a strong Q4 cash flow generation of EUR 69 million. Receivables, DSO is at 61 days, up seven days compared to December 2022. The normalization of the working capital is not yet fully completed post-COVID-19, mainly receivables, even though strong progress were achieved in Q4. Overall, EUR 30 million cash from working capital in Q4. EUR 63 million tax payment in 2023, lower than last year, but still high amount in relation to the adjusted net profit of EUR 44 million. It's all timing of tax payment in relation to prior year higher profit from COVID-19. Net CapEx, including leases, is decreasing 29 million year-over-year as planned. It includes EUR 62 million for Synnovis, with the ongoing setup of the new lab in London. Excluding Synnovis, the Q4 unlevered free cash flow conversion to EBITDA is at 77%. The Q4 unlevered free cash flow performance helps illustrate and reconfirm the strong cash flow generation of the SYNLAB model. Page 15, strong balance sheet. The balance sheet of the group expressed with the capital employed and capital resources view. The year-over-year EUR 300 million reduction of Capital Employed is mainly driven by the 2023 acquisitions and disposals, the normalization of the working capital, post-COVID, and the Goodwill Impairment in Germany. On the resources side, the net debt of the group, including EUR 620 million of leases, is now at EUR 1.34 billion, down EUR 235 million versus December 2022, of which EUR 336 million from the net proceeds of the 2023 disposals. The group has a strong balance sheet, with rounded EUR 220 million cash on hand and EUR 500 million of undrawn RCF at the end of December. EUR 520 million from the Term Loan A and B have been reimbursed in 2023. The net debt, page 16. The adjusted net debt is at EUR 1,303 million at the end of December 2023. The adjusted net debt reduction reflects EUR 68 million spent in acquisitions, offset by EUR 336 million net proceeds from disposal, the dividends paid to the SYNLAB AG shareholders, and the last twelve months pro forma EBITDA stands at EUR 449 million. The leverage ratio, debt to EBITDA, stands at 2.9 x, up 83 basis points compared to December 2022, but stable down 3 basis points compared to September 2023. This concludes the financial section of the presentation, and now hand it back to Mathieu for the business review. Thank you, Sami. So we can now dive into our main geographies, and we start with France. We reach in France, so it's 20% of our group revenues, and we reached EUR 524 million revenues in 2023, and an AOP of EUR 56 million, with a margin AOP at 10.7%. Q4 2023 decline in revenues versus Q4 2022, but AOP margin more than doubled in one year, despite lower COVID-19 and unfavorable price and inflation impacts, which reflects good progress on our cost management. As for 2024, a reduction of one cent on the B point started on January fifteenth, which is equivalent to a 3.8% annual price decrease. Moving on to Germany, on the next slide, also 20% of our revenues. In Germany, the revenue for 2023 was EUR 536 million. AOP and AOP margin came negative at -EUR 11.4 million and -2.1%, respectively. As mentioned previously, a portfolio review to improve performance throughout our business is actively ongoing. Some actions are progressing already, and restructuring provisions are negatively impacting our 2023 financials. Germany is under an acute focus in the group, and we trust our ongoing actions will restore profitability. The strong organic growth based on customer wins and contract management is very encouraging for us... On slide 20, South, which is 31% of the group revenue. Our annual revenue in the South segment was at EUR 803 million. AOP was EUR 71 million, resulting in a margin of 8.8%. So the AOP margin improved significantly in Italy and Portugal, and overall in all geographies except for Spain. Spain operations are under strong focus, and we are working also there to restore our margins. We have faced high inflation in the South region, which we were partly capable to offset through our increased static savings and through price increases. On the next page, we have North and East, which is 29% of our revenues. This closes our segment review with North and East segment reported revenues of EUR 770 million in 2023. The AOP came in at EUR 78.5 million, with a margin of 10.2%. In this segment, we saw a continued, particularly strong business growth of 12.5%. The growth was again driven by significant increases in testing volumes, which is about +5.9%, and prices also at +6.6%, with a good contribution overall of our four new growth initiatives. So then we can jump to page 23 to conclude today's presentation with the outlook for 2024. So this solid 2023 performance reinforces our perspectives for the future, relying on our strong core business of routine and specialty testing. We expect group revenues of around EUR 2.7 billion at the current perimeter, and this assumption is driven by continued strong underlying organic growth, which we now expect at around 4% for the full year. Our 2024 adjusted EBITDA margin is expected to be in the range of 17%-18%. Finally, we aim at a spend between EUR 50 million to up to EUR 100 million in M&A during 2024. In conclusion, we performed as expected in 2023, managing simultaneously a high organic growth, a recovery of our productivity, and significant portfolio reshaping. We're very confident about our operational and strategic trajectory. With this, I would like to hand back to the operator to open our line for the Q&A. Thank you. Ladies and gentlemen, if you do wish to ask a question, please press star one on your telephone keypad now. Once again, for an audio question, please press star one on your telephone keypad. If you wish to withdraw your question, you may do so by pressing star two to cancel. One moment, please, whilst any questions are being registered. Our first question comes from the line of Konstantin Lukic from NatWest Markets. Please go ahead. Your line is open. Hi, can you hear me? Yes, we can. Thank you for the presentation. I just wanted to ask you about the most recent news from the French Competition Authority on opening investigation into med biology sector. So if you could give us a bit more color on how it could impact French business and overall French bio sector. Thank you a lot. Okay. I can first refer you to the subsequent report of our annual report on page 69. But to answer your point, we indeed have been subjected to an investigation led by the French Autorité de la Concurrence, the French Antitrust Authority. This involves the lab industry, as you were mentioning, and us also. There are. The allegations are around anti-competitive practices in the medical biology sector. So of course, we are monitoring this case that just opened very carefully and currently, of course, collaborating with authorities. So it's very fresh, so we cannot really comment at this very early stage of the investigation. But we are, however, very confident that our French business has acted in full compliance with the applicable competition law. Thank you. Thank you. Once again, to register for any questions, it's star one on your telephone keypad. Our next question comes from the line of Harriet Veitch from Permira. Please go ahead. Your line is now open. Hi. Thank you very much for the call. I was just wondering, is there any update that you can share on the take-private process? Yes, Harriet. What we can share is that we are one regulatory authorization away from having full agreement. And this is Sweden, where we don't expect anything specific. They are just a bit delayed compared to all the other 17 authorizations we received, because they had a change of law, I think, earlier this year. So it's a bit of a particular new case for them, and that's what is explaining that they are slightly, let's say, later than the other ones. Once this authorization is obtained, then there is no other condition precedent for the consummation of the agreement by Cinven. Great. Thank you very much. Thank you. And our next question comes from the line of Paul Brannan. Please go ahead. Your line is open. Hi. Thanks for the call. My question was just similar to the last one. I was just wondering, can you give any updates on your capital structure as it relates to the take-private? I mean, do you expect any changes, such as the repayment of the Term Loan B? I will leave this one to Sami. Yeah. No, I mean, as part of the... No, all, all, it's still open, the reimbursement or not of the term loan B. In our refinancing, the performed in Q4, we kept this flexibility, and we have raised, Cinven has raised at Ephios Subco 3, enough cash to be able to complete 100% of the transaction. But if for whatever reason, the transaction is not at 100%, ultimately at the end, there will be enough cash at Ephios Subco 3 to be able to reimburse partially or totally the term loan B. But this is still not defined yet, and but all options are possible. Understood. Thanks. And is there any deadline related to that, by which if they're not at the 100%, that they will use the cash to repay the Term Loan B? Nope. No, not, not known. I mean, this is still the first things which is to happen is the consummation of the offer, and the next steps are still open. Okay. Thank you. Thank you. Once again, it's star one to register for any questions. As we have no more questions registered, I hand back to our speakers. Yeah, we can still leave some more time for more questions. We can wait a few more minutes. As a reminder, if you do have any audio questions, it is star one on your telephone keypad to register. Okay, well, it seems that we have exhausted the questions, so thank you for your attendance. Just, our corporate calendar next events are 8th of May for results of Q1 2024, and 17th of May for our AGM. Thank you very much, and have a good rest of the day. This concludes our presentation. Thank you all for attending. You may now disconnect.